We Care About
Your Health

Every year, modern society manufactures 10 trillion lbs of 84,000 chemicals that human bodies have never seen before. XCellAssay’s mission is to help you identify when you are exposed to chemicals that affect your health, and to provide you with personalized guidance to remove them from your surroundings.


Our People


Fred Schaufele, PhD

Managing Partner and Director of Scientific Operations


Irina Krylova, PhD

Director of Environmental Studies


Mei Ling

VP of Digital Technology

Press Release

  • March 2020

    The COVID-19 response has required the cancellation of the annual meeting of The Endocrine Society, at which Dr. Schaufele and Dr. Krylova had been scheduled to present XCellAssay studies. The Endocrine Society currently is considering alternative mechanisms to present “Advantages and Limitations of an Integrative Measurement for All Serum Androgens and Anti-Androgens” (from Dr. Schaufele and UCSF collaborators Dr. Armaiti and Dr. Huddleston) and “Dynamic Structural Model of Testosterone Entry into the Unliganded Androgen Receptor” (from Drs. Krylova, Schaufele and Guilbert).

  • February 2020

    XCellAssay announces the continuation of funding by the Partnership for Clean Competition (PCC) for the development of our technology for identifying persons exposed to known or unknown androgens or anabolic androgenic steroids. The PCC, which was founded by the U.S. Olympic & Paralympic Committee, the US Anti-Doping Agency, the National Football League and Major League Baseball, has awarded three research studies by Dr. Schaufele to develop the measurement capability as part of the PCC’s mission “to help generate the world’s most influential, effective and coveted methods and resources for detecting and deterring the use of performance enhancing substances by all athletes in all sports at all levels”.

  • January 2020

    Dr. Schaufele and his UCSF collaborators Drs. Armaiti and Huddleston will present the abstract “Advantages and Limitations of an Integrative Measurement for All Serum Androgens and Anti-Androgens” at the 2020 annual meeting of The Endocrine Society. The paper will describe the supporting data validating the androgen measurement technique for serum samples and its applications for detecting elevated androgen levels in patients with a PCOS diagnosis compared to women not meeting formal PCOS criteria.

  • January 2020

    XCellAssay announces renewal of its agreement for the right to negotiate an exclusive license with the UCSF Office of Innovation Ventures for the technology covered in US Patent #10,324,099 (Inventor, Dr. Fred Schaufele, co-Founder, XCellAssay). A prior freedom to operate analysis conducted with the Startup Legal Garage program of the University of California Hastings College of the Law indicated that no patents or patent applications were found at the time of the report that “appear to have issued claims or claims that are likely to issue that should be infringed by the XCA’s Product”.

Contact Us

XCellAssay is located in the MBC BioLabs incubator (formerly QB3@953)
beside the University of California San Francisco’s Mission Bay campus